Literature DB >> 20462367

Serum transthyretin levels in Swedish TTR V30M carriers.

Joel Buxbaum1, Intissar Anan, Ole Suhr.   

Abstract

Serum transthyretin (TTR) levels have been reported to be reduced in Portuguese and Japanese patients with TTR V30M familial amyloidotic polyneuropathy and pre-symptomatic carriers of the allele as well as in the carriers of a number of other mutant TTRs. The only published report of serum TTR levels in Swedish TTR V30M carriers suggested that serum TTR levels were elevated in a small number of cases. Since Swedish V30M carriers have a lower degree of clinical penetrance than those from other countries we wished to determine if the reportedly elevated serum TTR concentrations and the lower clinical penetrance were part of a pathologic process that differed between the Swedish carriers and those of other ethnic groups. We compared the serum TTR levels, as determined by ELISA, in 42 documented Swedish TTR V30M carriers with 16 control individuals from the same geographic area in northern Sweden. Serum TTR concentrations in the controls were statistically significantly higher than in the TTR V30M carriers, which were in the same range as those in African-Americans carrying the TTR V122I allele. Thus, Swedish TTR V30M carriers have the same reduction in serum TTR as do other ethnic groups carrying the same or other TTR mutations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462367     DOI: 10.3109/13506129.2010.483118

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  13 in total

1.  Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).

Authors:  Jacquelyn L Sikora; Mark W Logue; Gloria G Chan; Brian H Spencer; Tatiana B Prokaeva; Clinton T Baldwin; David C Seldin; Lawreen H Connors
Journal:  Hum Genet       Date:  2014-11-04       Impact factor: 4.132

2.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

3.  Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.

Authors:  Jacquelyn L S Hanson; Marios Arvanitis; Clarissa M Koch; John L Berk; Frederick L Ruberg; Tatiana Prokaeva; Lawreen H Connors
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

4.  ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.

Authors:  John J Chen; Joseph C Genereux; Song Qu; John D Hulleman; Matthew D Shoulders; R Luke Wiseman
Journal:  Chem Biol       Date:  2014-10-23

Review 5.  Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Abdel-Rahman Torky; Marios Matiakis; Mammad Mammadov; Hannes Melnyk; Alexander Vogt; Renato de Vecchis; Boris Bigalke; Walter Wohlgemuth; Sophie Mavrogeni; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

6.  Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.

Authors:  Cecília Monteiro; Jaleh S Mesgazardeh; João Anselmo; Joana Fernandes; Marta Novais; Carla Rodrigues; Gabriel J Brighty; David L Powers; Evan T Powers; Teresa Coelho; Jeffery W Kelly
Journal:  JCI Insight       Date:  2019-06-20

Review 7.  Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.

Authors:  Caleb J Hood; Nicholas S Hendren; Rose Pedretti; Lori R Roth; Lorena Saelices; Justin L Grodin
Journal:  Curr Heart Fail Rep       Date:  2022-08-05

8.  Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study.

Authors:  Marzieh Araghi; Martin J Shipley; Atul Anand; Nicholas L Mills; Mika Kivimaki; Archana Singh-Manoux; Adam Tabák; Séverine Sabia; Eric J Brunner
Journal:  Neurol Sci       Date:  2021-03-26       Impact factor: 3.830

9.  A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.

Authors:  Malin Olsson; Nina Norgren; Konen Obayashi; Violaine Plante-Bordeneuve; Ole B Suhr; Kristina Cederquist; Jenni Jonasson
Journal:  BMC Med Genet       Date:  2010-09-14       Impact factor: 2.103

10.  Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy.

Authors:  E Panayiotou; R Papacharalambous; A Antoniou; G Christophides; L Papageorgiou; E Fella; S Malas; T Kyriakides
Journal:  Biochem Biophys Rep       Date:  2016-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.